Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 5/20 | 0.68 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | TMIGD3 | P0DMS9 | 4/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.52 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.51 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5478336 | 0.87 | RAB9A (0.59) | ADORA1ADORA2AKDM4EALDH1A1HPGD | |
| SCHEMBL5483666 | 0.82 | EPHB4 (0.56) | ADORA1ADORA2AKDM4EALDH1A1HPGD | |
| SCHEMBL8240492 | 0.81 | TMIGD3 (0.52) | ADORA1ADORA2AKDM4EALDH1A1HPGD | |
| SCHEMBL18189922 | 0.77 | ALDH1A3 (0.58) | ADORA1ADORA2AKDM4EALDH1A1HPGD | |
| SCHEMBL9938832 | 0.77 | KDM4E (0.50) | ADORA1ADORA2AKDM4EALDH1A1HPGD | |
| SCHEMBL5412238 | 0.77 | AURKA (0.60) | KDM4EALDH1A1HPGDHSD17B10GLA | |
| SCHEMBL14006694 | 0.77 | ADORA2A (0.43) | ADORA1ADORA2AKDM4EALDH1A1HPGD | |
| SCHEMBL17536352 | 0.77 | PIK3CA (0.59) | KDM4ERAB9AAURKANPC1SMN1; SMN2 | |
| SCHEMBL20600721 | 0.76 | ADORA2A (0.71) | ADORA1ADORA2AKDM4EALDH1A1HPGD | |
| SCHEMBL9082442 | 0.73 | ALDH1A3 (0.68) | ADORA1ADORA2AKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009832-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN, INC. | 2005-01-13 | — | — | US | claimed |
| US-20040220189-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhbitors | SUGEN, INC. | 2004-11-04 | — | — | US | claimed |
| US-7576085-B2 | Imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576085-B2 | Imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2009-08-18 | — | — | US | disclosed |
| US-7432265-B2 | Imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432265-B2 | Imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| EP-1543008-B1 | IMIDAZOPYRAZINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORP (US) | 2007-11-07 | — | — | EP | disclosed |
| US-7186832-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186832-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186832-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7157460-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157460-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20060106023-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2006-05-18 | — | — | US | disclosed |
| US-20060106023-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2006-05-18 | — | — | US | disclosed |
| US-20050009832-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN, INC. | 2005-01-13 | — | — | US | disclosed |
| US-20040220189-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhbitors | SUGEN, INC. | 2004-11-04 | — | — | US | disclosed |
| US-20040063715-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2004-04-01 | — | — | US | disclosed |
| US-20040063715-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009832-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | MAP3K8, MAP3K2, MAP3K5 | ADORA1 3042/4885ADORA2A 1341/4885KDM4E 663/4885 |
| US-20040220189-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhbitors | MAP3K8, MAP4K4, MAP3K2 | ADORA1 2666/4885ADORA2A 1510/4885KDM4E 887/4885 |
| US-20040063715-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | CDK2, CDKN1A, CDK1 | ADORA1 2172/4885ADORA2A 1932/4885KDM4E 677/4885 |
| US-20060106023-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | CDK2, CDKN1A, CDK1 | ADORA1 3721/4885ADORA2A 2475/4885KDM4E 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.